<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135990">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662180</url>
  </required_header>
  <id_info>
    <org_study_id>PRORAILS trial</org_study_id>
    <nct_id>NCT01662180</nct_id>
  </id_info>
  <brief_title>Predicting Ovarian Response in Artificial Insemination With Low Stimulation</brief_title>
  <official_title>Predicting Ovarian Response in Artificial Insemination With Low Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isala Klinieken</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Isala Klinieken</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This large prospective multi-center cohort study aims to identify patient's characteristics
      that significantly influence ovarian response to mild stimulation with a fixed dose of 75 IU
      recombinant FSH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, open-label, prospective cohorts study. Patients with a regular indication
      for COH/IUI (controlled ovarian stimulation/ intra uterine insemination) will be asked to
      participate. Patient's characteristics will be documented including age, weight, BMI,
      smoking status, cycle day 2 3 or 4 FSH /Estradiol levels, antral follicle count, and AMH.
      AMH and FSH/Estradiol will be determined centrally after completion of inclusion of all
      patients in the study. All patients will receive a fixed 75 IU recFSH per day conform normal
      stimulation protocol starting from cycle day 3, 4 or 5 after exclusion of ovarian cysts by
      ultrasound. Ovarian response will be documented by ultrasound only. Once the dominant
      follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and
      insemination will be scheduled 36-42 hours later. Cancellation criteria will be defined
      according to the national guidelines provided by the NVOG (7).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To assess the relationship between AMH serum levels and ovarian response</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>(defined by the number of dominant follicles &gt;15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH. All follicles &gt; 11 mm will be documented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the relationship between age, weight, BMI, smoking, AFC, FSH/E2 on CD3 and ovarian response</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>(defined by the number of dominant follicles &gt;15mm) in IUI cycles stimulated with a fixed dose of 75 IU recFSH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate per started cycle.</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>From start of the menstrual cycle until a positive heartbeat registered at 12 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate per started cycle.</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>From start of the menstrual cycle until  positive heartbeats registered at 12 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate per started cycle.</measure>
    <time_frame>five months</time_frame>
    <safety_issue>No</safety_issue>
    <description>miscarriage up to 16 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate per stimulated cycle</measure>
    <time_frame>one menstrual cycle, one month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Subfertile couples</arm_group_label>
    <description>Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles
All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5.   Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicle Stimulating Hormone</intervention_name>
    <description>All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.</description>
    <arm_group_label>Subfertile couples</arm_group_label>
    <other_name>Puregon [Merck Sharp &amp; Dohme bv]</other_name>
    <other_name>Gonal -F [Serono Benelux bv]</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample tested for FSH, E2 and AMH
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subfertile couples presenting at fertility clinics with an indication for IUI in
        stimulated cycles
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  couples with unexplained or mild male subfertility (1-3) and a spontaneous chance of
             conception below 40% (Hunault score).

          -  Unexplained subfertility including minimal to mild endometriosis (AFS grade 1 or 2)
             is defined as the failure to conceive after at least one year of unprotected
             intercourse whereas the standard fertility work-up was unable to detect any factors
             that might influence fertility negatively.

          -  semen analysis should be normal according to the WHO guidelines (8),

          -  ovulation should be documented (by BBT charts, ovulation detection by ultrasound or
             normal luteal progesterone values),

          -  tubal patency should be confirmed (HSG, laparoscopy or fertiloscopy) and when a
             postcoital test was performed a cervical factor should have been excluded.

          -  Mild male subfertility is defined as abnormal semen parameters according to the WHO
             (8) but an average total motile sperm account before processing of at least 10
             million.

        Exclusion Criteria:

          -  Hunault score â‰¥ 40%

          -  Endometriosis AFS grade 3 or 4

          -  Contra-indications for the use of gonadotrophins (cysts larger than 2    cm, allergy
             for gonadotrophins)

          -  Total motile sperm count after sperm processing below 1 million

          -  Women aged younger than eighteen years or older than 45 years.

          -  Previous treatment with COH/IUI for treating current subfertility

          -  Unable to speak or read the Dutch language
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Cohlen, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala Klinieken</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maaike M Bloemendal, Drs.</last_name>
    <phone>0031384247506</phone>
    <email>m.m.bloemendal@isala.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben Cohlen, Dr.</last_name>
    <phone>0031384247570</phone>
    <email>b.cohlen@isala.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <state>Po 95500</state>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugenie Kaaijk, dr.</last_name>
      <phone>0031205993481</phone>
      <email>e.m.kaaijk@olvg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Logtenberg</last_name>
      <phone>003120-5999111</phone>
      <email>s.l.m.logtenberg@olvg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenie Kaaijk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>PO Box 10400</state>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maaike Bloemendal, Drs.</last_name>
      <phone>0031384247506</phone>
      <email>m.m.bloemendal@isala.nl</email>
    </contact>
    <contact_backup>
      <last_name>Henriette Hulsebos</last_name>
      <phone>0031384247783</phone>
      <email>h.j.m.hulsebos@isala.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Cohlen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>PO box 1350</state>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minouche van Rumste, dr.</last_name>
      <phone>003140 239 71 00</phone>
      <email>minouche.v.rumste@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Milou Peters</last_name>
      <phone>00316-5102 8887</phone>
      <email>milou.peters@catharinaziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Minouche van Rumste, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>PO box 22660</state>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fulco van der Veen, prof. dr.</last_name>
      <phone>003120 - 566 4287</phone>
      <email>f.vanderveen@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tessa de Vries</last_name>
      <phone>00316 - 23799274</phone>
      <email>t.s.devries@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Fulco van der Veen, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <state>PO box 7057</state>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelis Lambalk, prof. dr.</last_name>
      <phone>0031204444444</phone>
      <email>cb.lambalk@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Angelique de Vos-Brouwer</last_name>
      <phone>003120-4442180</phone>
      <email>m.devos-brouwer@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Cornelis Lambalk, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>PO box 85500</state>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Broekmans, prof. dr.</last_name>
      <phone>088-7551041</phone>
      <email>f.broekmans@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marian Kosterman</last_name>
      <phone>088-7555555</phone>
      <email>M.J.T.Kosterman@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Broekmans, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>st Elizabeth Gasthuis</name>
      <address>
        <city>Tilburg</city>
        <state>PO box 90151</state>
        <zip>5000 LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Smeenk, dr.</last_name>
      <phone>0031013539 30 06</phone>
      <email>j.smeenk@elizabeth.nl</email>
    </contact>
    <investigator>
      <last_name>Jesper Smeenk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.studies-obsgyn.nl/prorails</url>
    <description>PRORAILS website</description>
  </link>
  <reference>
    <citation>Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-uterine insemination for male subfertility. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000360. Review.</citation>
    <PMID>17943739</PMID>
  </reference>
  <reference>
    <citation>Verhulst SM, Cohlen BJ, Hughes E, Te Velde E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001838. Review.</citation>
    <PMID>17054143</PMID>
  </reference>
  <reference>
    <citation>Tummon IS, Asher LJ, Martin JS, Tulandi T. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril. 1997 Jul;68(1):8-12.</citation>
    <PMID>9207576</PMID>
  </reference>
  <reference>
    <citation>Freiesleben NL, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Loft A, Bangsboll S, Pinborg A, Budtz-JÃ¸rgensen E, Andersen AN. Predictors of ovarian response in intrauterine insemination patients and development of a dosage nomogram. Reprod Biomed Online. 2008 Nov;17(5):632-41.</citation>
    <PMID>18983747</PMID>
  </reference>
  <reference>
    <citation>la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Rosendahl M, Loft A, Bangsboll S, Pinborg A, Nyboe Andersen A. Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study. Hum Reprod. 2009 Oct;24(10):2523-30. Epub 2009 Jul 14.</citation>
    <PMID>19602518</PMID>
  </reference>
  <reference>
    <citation>Freiesleben Nl, Rosendahl M, Johannsen TH, LÃ¸ssl K, Loft A, BangsbÃ¸ll S, Friis-Hansen L, Pinborg A, Andersen AN. Prospective investigation of serum anti-MÃ¼llerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study. Reprod Biomed Online. 2010 May;20(5):582-7. doi: 10.1016/j.rbmo.2010.02.007. Epub 2010 Feb 12.</citation>
    <PMID>20303323</PMID>
  </reference>
  <reference>
    <citation>Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010 May-Jun;16(3):231-45. Epub 2009 Nov 24. Review.</citation>
    <PMID>19934213</PMID>
  </reference>
  <reference>
    <citation>La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. Epub 2009 Sep 30. Review.</citation>
    <PMID>19793843</PMID>
  </reference>
  <reference>
    <citation>Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-MÃ¼llerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012 Mar;27(3):631-6. Epub 2012 Jan 11.</citation>
    <PMID>22238112</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 12, 2012</lastchanged_date>
  <firstreceived_date>July 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isala Klinieken</investigator_affiliation>
    <investigator_full_name>M. Bloemendal</investigator_full_name>
    <investigator_title>drs.</investigator_title>
  </responsible_party>
  <keyword>subfertility, IUI, rec FSH, FSH, E2, AMH</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
